Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JTC confident after revenues, earnings jump

(Sharecast News) - JTC posted a jump in full-year sales and profits on Tuesday, as it reiterated plans to double the size of the business by 2027. The provider of fund administration services said revenues in the year to 31 December rose 18.6% to £305.4m, while underlying earnings before interest and amortisation was 18.4% stronger at £101.7m.

Pre-tax profits rose 17.8% to £71.6m on the same basis.

The performance was boosted by a near 16% jump in new business wins to £35.7m, as well as a raft of deals. A total of six acquisitions were announced or completed during the year.

Its institutional client services division reported net organic growth of 9.9%, while revenues surpassed £100m in the private client services unit for the first time.

2024 was the first year of JTC's long-term business plan, dubbed Cosmos, under which it is aiming to reach revenues of more than £500m and underlying EBITDA of more than £170m by the end of 2027.

Nigel Le Quesne, chief executive, said: "We have made a fast start towards our goal of doubling the size of the group for the third time since IPO. We delivered record new business wins, organic growth above our upgraded guidance and a strong margin, even as we continue to invest in growth."

Looking to the current year, JTC - which made its market debut in 2018 - said it had made a "good start, with strong organic growth trends set to continue".

Vivek Raja, analyst at Shore Capital, said the results were "broadly" in line with expectations.

He continued: "The trading outlook is confident and positive, as JTC has made a good start to the 2025 full year, with a strong new business pipeline.

"Having safely navigated several crises in the past, JTC has a globally diverse business with pockets of defence growth, so we are reasonably confident the company can successfully navigate changes which are currently carving through the world order."

Shore Capital has a 'buy' rating on the FTSE 250 stock.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.